CATALENT, INC. (NYSE:CTLT) Files An 8-K Other EventsItem 8.01 Other Items.
On September 25, 2017, Catalent, Inc. (the “Company”) issued a press release announcing the underwritten public offering of $250 million of its common stock. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 8.01 Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit No. |
Description |
| 99.1 | Press Release of Catalent, Inc., dated September 25, 2017, announcing underwritten public offering of common stock. |
2
EXHIBIT LIST
3
Catalent, Inc. ExhibitEX-99.1 2 d461574dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalent,…To view the full exhibit click here
About CATALENT, INC. (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.